Array BioPharma market cap is $10.7 b, and annual revenue was $173.77 m in FY 2018

Array BioPharma Gross profit (Q3, 2019)63.6 M

Array BioPharma Gross profit margin (Q3, 2019), %98.4%

Array BioPharma Net income (Q3, 2019)-37.5 M

Array BioPharma EBIT (Q3, 2019)-37.5 M

Array BioPharma Cash, 31-Mar-201996.6 M

Array BioPharma EV10.7 B

Array BioPharma revenue was $173.77 m in FY, 2018

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|

## Revenue | 85.1m | 69.6m | 42.1m | 51.9m | 137.9m | 150.9m | 173.8m |

| 23% | 166% | |||||

## Cost of goods sold | 24.3m | 30.1m | 46.0m | 44.4m | 23.2m | 35.4m | 59.4m |

## Gross profit | 60.9m | 39.5m | (3.9m) | 7.5m | 114.7m | 115.5m | 114.4m |

| 72% | 57% | (9%) | 14% | 83% | 77% | 66% |

## R&D expense | 56.7m | 59.4m | 49.8m | 54.4m | 160.7m | 178.2m | 185.8m |

## General and administrative expense | 15.2m | 19.6m | 21.9m | 31.4m | 36.3m | 39.3m | 58.5m |

## Operating expense total | 71.9m | 79.0m | 71.7m | 4.2m | 196.9m | 217.5m | 244.3m |

## EBIT | (11.0m) | (39.5m) | (75.6m) | 3.3m | (82.2m) | (102.1m) | (129.9m) |

| (13%) | (57%) | (180%) | 6% | (60%) | (68%) | (75%) |

## Interest expense | 11.6m | 11.3m | 6.1m | 10.6m | 14.7m | 15.1m | |

## Interest income | 32.0k | 55.0k | 77.0k | 68.0k | 243.0k | 796.0k | 4.5m |

## Pre tax profit | (23.6m) | ||||||

## Income tax expense | 2.3m | ||||||

## Net Income | (23.6m) | (61.9m) | (85.3m) | 9.4m | (92.8m) | (116.8m) | (147.7m) |

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|

## Net Income | (23.6m) | (61.9m) | (85.3m) | 9.4m | (92.8m) | (116.8m) | |

## Depreciation and Amortization | 5.1m | 4.4m | 4.5m | 3.7m | 1.5m | 2.1m | 2.2m |

## Accounts Receivable | (8.5m) | 4.2m | (7.6m) | (33.0m) | 8.0m | (805.0k) | |

## Accounts Payable | 2.0m | (1.3m) | 1.9m | (1.1m) | 3.9m | (1.0m) | 5.7m |

## Cash From Operating Activities | (33.5m) | (87.1m) | (71.7m) | (5.8m) | (70.1m) | (39.4m) | (119.8m) |

## Purchases of PP&E | (1.4m) | (2.3m) | (2.6m) | (2.5m) | (3.2m) | (3.5m) | (1.2m) |

## Cash From Investing Activities | (18.7m) | (16.4m) | 2.5m | (58.0m) | 66.0m | (58.1m) | (191.0m) |

## Long-term Borrowings | (4.3m) | (92.7m) | (14.5m) | ||||

## Cash From Financing Activities | 60.0m | 108.4m | 77.1m | 50.9m | 5.0m | 166.8m | 299.6m |

## Net Change in Cash | 7.7m | 4.9m | 7.9m | (12.9m) | 907.0k | 69.3m | (11.2m) |

## Interest Paid | 7.0m | 6.6m | 4.3m | 4.5m | 4.5m | 4.4m | 4.0m |

## Income Taxes Paid | 2.3m |

USD | Q1, 2012 |
---|---|

## Financial Leverage | -0.7 x |